Evidence map›Paper›PMID 30702923›Full record

ArticleAmerican journal of respiratory cell and molecular biology2019

Attenuation of Allergen-, IL-13-, and TGF-α-induced Lung Fibrosis after the Treatment of rIL-15 in Mice.

Sathisha Upparahalli Venkateshaiah, Rituraj Niranjan, Murli Manohar, Alok K Verma, Hemanth K Kandikattu, Joseph A Lasky, Anil Mishra

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Sex Hormones and Lung Inflammation.Advances in experimental medicine and biology · 2021
    Article
  10. Update in Interstitial Lung Disease 2019.American journal of respiratory and critical care medicine · 2020
    Review
  11. IL-15 immunotherapy is a viable strategy for COVID-19.Cytokine & growth factor reviews · 2020
    Review
  12. Interleukin (IL)-15 significance in aging associated asthma pathogenesis.International journal of cell biology and physiology · 2020
    Article
  13. Chronic Pancreatitis and the Development of Pancreatic Cancer.Endocrine, metabolic & immune disorders drug targets · 2020
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sathisha Upparahalli Venkateshaiah1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.
Rituraj Niranjan2 Indian Council of Medical Research, Vector Control Research Centre, Puducherry, India.
Murli Manohar1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.ORCID 0000-0002-5470-6426
Alok K Verma1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.
Hemanth K Kandikattu1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.
Joseph A Lasky1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.
Anil Mishra1 Section of Pulmonary Medicine, Department of Medicine, Tulane Eosinophilic Disorder Center, New Orleans, Louisiana; and.ORCID 0000-0003-4266-4684
Indian Council of Medical Research · IN

Funding

Role of IL-15 in the Pathogensis of Eosinophilic EsophagitisR01AI080581 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI MISHRA, ANIL · 2009 to 2023
$4.9M
NIAID NIH HHS R01 AI080581
6 · The paper itself

Abstract

Endogenous IL-15 deficiency promotes lung fibrosis; therefore, we examined the effect of induced IL-15 in restricting the progression of lung fibrosis. Our objective in this work was to establish a novel therapeutic molecule for pulmonary fibrosis. Western blot, qPCR, and ELISA were performed on the lung tissues of IL-15-deficient mice, and recombinant IL-15 (rIL-15)-treated CC10-IL-13 and CC10-TGF-α mice, and allergen-challenged CC10-IL-15 mice were examined to establish the antifibrotic effect of IL-15 in lung fibrosis. We show that endogenous IL-15 deficiency induces baseline profibrotic cytokine and collagen accumulation in the lung, and pharmacological delivery of rIL-15 downregulates

Indexed as

Airway RemodelingAllergensAnimalsAspergillus fumigatusBronchiCollagenDoxycyclineInterleukin-13Interleukin-15LungMice, Inbred BALB CMice, TransgenicNuclear Receptor Subfamily 1, Group F, Member 3ProteinsPulmonary FibrosisRecombinant Fusion ProteinsAllergensALT-803CollagenDoxycyclineInterleukin-13Interleukin-15Nuclear Receptor Subfamily 1, Group F, Member 3ProteinsRecombinant Fusion ProteinsRecombinant ProteinsRorc protein, mouseTransforming Growth Factor alphaallergenfibrosisIL-13lungTGF-β

Identifiers

PMID30702923
PMCPMC6604217
OpenAlexW2913182714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.